Patients in the Netherlands Face Lengthening Wait Times for New Treatments
Average wait time for new medications has reached 459 days, highlighting accessibility issues.
Patients in the Netherlands are facing increasing delays in accessing new medications.
The average wait time for new drugs has now extended to 459 days, as reported by the EFPIA Patients W.A.I.T. Indicator 2024. Between 2020 and 2023, the European Medicines Agency (EMA) approved a total of 173 drugs for the European market.
Of these, only 100 have become accessible to patients in the Netherlands.
This situation reflects ongoing challenges within the Dutch healthcare system regarding timely access to innovative treatments and medications.
The trend raises significant concerns about the impact of delayed access on patient outcomes and the overall effectiveness of healthcare delivery in the country.
The average wait time for new drugs has now extended to 459 days, as reported by the EFPIA Patients W.A.I.T. Indicator 2024. Between 2020 and 2023, the European Medicines Agency (EMA) approved a total of 173 drugs for the European market.
Of these, only 100 have become accessible to patients in the Netherlands.
This situation reflects ongoing challenges within the Dutch healthcare system regarding timely access to innovative treatments and medications.
The trend raises significant concerns about the impact of delayed access on patient outcomes and the overall effectiveness of healthcare delivery in the country.
